
Oculis gains FDA clearance for Privosegtor MS trials
Key points
- Oculis says the FDA has cleared its IND application for Privosegtor's clinical development in acute multiple sclerosis (MS) relapses.
- Oculis last closed at $7.64 on November 13, up 1.87% during that session; post-announcement trading was not yet available.
- The proposed program covers optic neuritis and other MS relapses, with a five-day dosing schedule and a December 8 R&D Day planned.
Oculis (NASDAQ:OCS) said the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for Privosegtor in acute multiple sclerosis (MS) relapses, allowing clinical development to proceed.
Oculis said the FDA supported a development strategy covering optic neuritis and other MS relapses, including ambulatory relapses, while permitting the company to cross-reference existing ophthalmology data.
The completed Phase 2 ACUITY trial enrolled patients with optic neuritis both with and without MS and showed improved visual function, preserved retinal ganglion cell layer integrity, and reduced blood markers of nerve-fiber injury and supporting-cell activation.
The proposed treatment schedule is 3 mg/kg once daily for five days, with a primary endpoint assessed as early as three months; no adverse events in ACUITY led to drug withdrawal or study discontinuation.
Privosegtor is also being evaluated through Oculis' PIONEER program, which includes two registrational optic neuritis trials, with PIONEER-1 enrolling patients and PIONEER-2 planned for the fourth quarter of 2026.
Oculis' wider pipeline includes licaminlimab for dry eye disease, while the company reported $252 million in cash, cash equivalents and short-term investments at September 30, 2026, ahead of its scheduled December 8 R&D Day.



